Characterization of four basic models of indirect pharmacodynamic responses.
about
Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers.Pharmacodynamic modelling of biomarker data in oncology.Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism.Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models.Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.PKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy developmentQuantitative Systems Pharmacology Model of NO Metabolome and Methemoglobin Following Long-Term Infusion of Sodium Nitrite in HumansBasic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.Prediction of exposure-response relationships to support first-in-human study design.Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1α,25-Dihydroxyvitamin D3 in Mice.The method of averaging applied to pharmacokinetic/pharmacodynamic indirect response models.A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.Pharmacokinetics and pharmacodynamics of 3,3'-diindolylmethane (DIM) in regulating gene expression of phase II drug metabolizing enzymes.PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.Integrated model of hepatic and peripheral glucose regulation for estimation of endogenous glucose production during the hot IVGTT.Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models.Landmark and longitudinal exposure-response analyses in drug development.Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models.
P2860
Q32038981-22E0640A-3679-4880-8851-CA259BFADA72Q34241935-81662EE1-4783-44B6-9461-CC363D27506DQ34335692-A98AF209-1D8D-405F-9243-D6304B8486D0Q34700879-781CC8C9-6F1F-4C16-825B-C677D583AEC1Q34918726-7989505A-71D6-4960-97EB-7616C63B8D14Q35363649-13A902E3-6D99-4C32-87A5-B9E3E720FA42Q35449502-94A1965A-BB2B-4345-86C8-0002C040D1CCQ35768386-345C37E2-7C40-4048-9055-BD6BA0A7E83EQ35802149-1D670F5A-F730-4587-B147-43CAAF0E77DFQ35865449-C3DF980F-B586-43C0-95C1-60C3F6FFDCDAQ36407822-7A3C483B-8C83-4C9E-995E-13AC628BF9E9Q36861319-6405B88C-9BBF-4154-AB06-88C935826C92Q37065414-15864A26-1E6B-41FF-9962-164BD1B35F29Q37170126-9D38FD24-1591-4DD4-A49E-B598DB5F99C3Q37802266-D666F1CC-95EC-4527-BF4A-906BA77C8627Q38204833-20830263-C2CD-4186-93FA-A3767CF14949Q38716344-AC52F0F2-4635-4B5D-943A-6C0A2FE4F9B1Q38726711-AC0FD8B1-FA10-438E-92BB-06EF895FB99CQ39175455-6094240B-0E2E-45A5-BD61-8A992BC73F8AQ39477395-5813E2F7-96C1-4443-A998-3EAEBBB40535Q39809986-4657352E-F4A1-4BE6-9C1B-366982261DD8Q40299746-B91152D4-8226-4D8C-AB88-048C534A4837Q40769508-E78A7516-09FC-4519-807F-56BFB18DDFFFQ40794894-E2226ECD-0D2C-451F-AC83-98355F51BAAAQ41928814-7A726707-46D6-4A4F-A02A-345BECAE129EQ42104275-306BB292-DF37-4438-B44C-1B8AF1A03C9DQ42479231-42FD23CD-99BD-489F-A327-C99551AADDA1Q43073275-57C9265E-A9EC-4905-86D4-4ABD2CFAD687Q45211549-23995E97-77E0-4BB2-A9F0-BAF2FDDFB5FBQ46845790-5EC1DEC6-8C58-4445-9C30-B966B4EE5797Q48090138-A8187C6E-8FF3-431C-873D-1321D61301C3Q52082022-BC9809D7-013C-47C8-9424-A57DF7EE083C
P2860
Characterization of four basic models of indirect pharmacodynamic responses.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Characterization of four basic models of indirect pharmacodynamic responses.
@en
Characterization of four basic models of indirect pharmacodynamic responses.
@nl
type
label
Characterization of four basic models of indirect pharmacodynamic responses.
@en
Characterization of four basic models of indirect pharmacodynamic responses.
@nl
prefLabel
Characterization of four basic models of indirect pharmacodynamic responses.
@en
Characterization of four basic models of indirect pharmacodynamic responses.
@nl
P2860
P356
P1476
Characterization of four basic models of indirect pharmacodynamic responses.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF02353483
P577
1996-12-01T00:00:00Z